Importer of Controlled Substances, Notice of Application, United States Pharmacopeial Convention, 17230 [2013-06318]
Download as PDF
<![CDATA[
17230
Federal Register / Vol. 78, No. 54 / Wednesday, March 20, 2013 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Application, Noramco Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on July 22, 2011, Noramco Inc.,
1440 Olympic Drive, Athens, Georgia
30601, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
srobinson on DSK4SPTVN1PROD with NOTICES
Phenylacetone (8501) ..................
Thebaine (9333) ...........................
Noroxymorphone (9668) ..............
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
18:04 Mar 19, 2013
Jkt 229001
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–06330 Filed 3–19–13; 8:45 am]
II
II
II
II
II
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
The company plans to import
Thebaine (9333) analytical reference
standards for distribution to its
customers. The company plans to
import an intermediate form of
Tapentadol (9780) to bulk manufacture
Tapentadol for distribution to its
customers. The company plans to
import Phenylacetone (8501) and Poppy
Straw Concentrate (9670) to
manufacture other controlled
substances.
Comments and request for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule II, which
fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C.
952(a)(2)(B) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 19, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
VerDate Mar<14>2013
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Application, United States
Pharmacopeial Convention
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on January 21, 2013, United States
Pharmacopeial Convention, 12601
Twinbrook Parkway, Rockville,
Maryland 20852, made application to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug
Schedule
Norlevorphanol (9634) ..................
Levomethorphan (9210) ...............
Difenoxin (9168) ...........................
I
II
II
The company plans to import the
listed controlled substances in bulk
powder form from foreign sources for
the manufacture of analytical reference
standards for sale to their customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I and II,
which falls under the authority of
section 1002(a)(2)(B) of the Act (21
U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR
§ 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 19, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic classes of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–06318 Filed 3–19–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Registration, Noramco, Inc.
By Notice dated October 9, 2012, and
published in the Federal Register on
October 18, 2012, 77 FR 64142,
Noramco, Inc., 500 Swedes Landing
Road, Wilmington, Delaware 19801–
4417, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances:
Drug
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
Schedule
II
II
II
II
The company plans to import raw
Opium (9600) and Poppy Straw
concentrate (9670) to manufacture other
controlled substances. The company
plans to import Tapentadol (9780) in
intermediate form for the bulk
manufacture of Tapentadol (9780) for
distribution to its customers. The
company plans to import Phenylacetone
(8501) in bulk for the manufacture of a
controlled substance.
Comments and requests for hearings
on applications to import narcotic raw
E:\FR\FM\20MRN1.SGM
20MRN1
]]>Agencies
[Federal Register Volume 78, Number 54 (Wednesday, March 20, 2013)]
[Notices]
[Page 17230]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06318]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances, Notice of Application, United
States Pharmacopeial Convention
Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this
is notice that on January 21, 2013, United States Pharmacopeial
Convention, 12601 Twinbrook Parkway, Rockville, Maryland 20852, made
application to the Drug Enforcement Administration (DEA) to be
registered as an importer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Norlevorphanol (9634)...................... I
Levomethorphan (9210)...................... II
Difenoxin (9168)........................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
bulk powder form from foreign sources for the manufacture of analytical
reference standards for sale to their customers.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedules I and II, which falls under the
authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B))
may, in the circumstances set forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the proposed registration and may, at
the same time, file a written request for a hearing on such application
pursuant to 21 CFR Sec. 1301.43 and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 19, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic classes of any controlled substances
in schedules I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-06318 Filed 3-19-13; 8:45 am]
BILLING CODE 4410-09-P
